JPMorgan Starts ConforMIS (CFMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall Street rallies as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UPDATE: Oppenheimer Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:40 AM EDT(Updated - July 27, 2015 9:12 AM EDT)
Oppenheimer initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating and a price target of $26.
Analyst Steven Lichtman said, "CFMS's unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total... More
Wells Fargo Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:38 AM EDTWells Fargo initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating.
For an analyst ratings summary and ratings history on ConforMIS click here. For more ratings news on ConforMIS click here.
Shares of ConforMIS closed at $22.12 yesterday.
... MoreUPDATE: Canaccord Genuity Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:37 AM EDT(Updated - July 27, 2015 8:47 AM EDT)
Canaccord Genuity initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.00.
Analyst William J. Plovanic said, "We believe ConforMIS is a disruptive technology in the multi-billion dollar global orthopedic implant market.... More
Deutsche Bank Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:36 AM EDTDeutsche Bank initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.
Analyst Kristen Stewart said, "ConforMIS is an orthopedic manufacturer of fully customized implants utilizing its iFit technology--iFit design, iFit printing (3D printing), and iFit just-in-time... More
